Eyecare

SightGlass Vision Releases First White Paper on Diffusion Optics Technology

Groundbreaking Diffusion Optics Technology (DOT 0.2) spectacle lenses, clinically proven to slow myopia progression in children.

Published

8 months ago

September 21, 2023

Press Releases

SightGlass Vision Releases First White Paper on Diffusion Optics Technology

(PRESS RELEASE) LOS ALTOS, CA — SightGlass Vision today announced the release of its first white paper regarding the company’s Diffusion Optics Technology^™(DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.

The in-depth paper explains the relationship between artificially high contrast signals at the retina and myopia progression. This groundbreaking research led to the development of DOT to manage such contrast, now clinically proven via the pivotal CYPRESS study to slow myopia progression in children from age six. Its efficacy is particularly of note for the youngest patients, who would typically experience the fastest progression.

The white paper can be read online or downloaded as a PDF here

“Harnessing the power of contrast management is a revolutionary approach to controlling myopia. Our DOT spectacle lenses are now paving a new path to reducing myopia progression from an early age. This white paper goes deeper into the science to explain the mechanisms of action, helping eye care professionals better understand the innovation,” said SightGlass Vision Vice President of Clinical, Medical & Professional Affairs Marcella McParland.

“As a more recent entrant into the myopia management field, our Diffusion Optics Technology paper will help disseminate the substantial science behind contrast management and its application. DOT spectacle lenses present a compelling alternative to existing solutions for slowing myopia’s progression in children,” added Andrew Sedgwick, SightGlass Vision’s CEO.

Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy^1,2,3,4 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.

For more information, visit SightGlassVision.com.

click to Comment(Comment)

Up Next

National Advertising Division Recommends MacuHealth Discontinue or Modify Certain Claims for Several Brands of Eye Health Dietary Supplements

Don't Miss

CooperVision Opens Applications for 2024 Best Practices Honorees and Student Scholarship Recipients

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.